constipation%20in%20adults%20-%20chronic%20functional
CONSTIPATION IN ADULTS - CHRONIC FUNCTIONAL
Constipation is an unsatisfactory defecation distinguished by difficult stool passage, infrequent stools or both.
Difficult stool passage may include straining, feeling of difficulty in passing stool, incomplete evacuation, lumpy/hard stools, prolonged time to defecate, need for manual maneuver to pass stool, abdominal discomfort and feeling of anorectal blockade.
Chronic constipation is considered when symptoms of constipation have existed ≥3 months.
Symptoms of chronic constipation may be due to dysfunction of intestinal motility, visceral sensitivity, anorectal musculature or the enteric nervous system.

Constipation%20in%20adults%20-%20chronic%20functional Patient Education

Patient Education

  • Engage in regular exercise
  • Inform patient that therapy is comprehensive in order to restore the defecation physiology
  • Reassure and explain about normal bowel habits and routine toileting
    • Encourage patients to defecate when colonic activity is highest (eg upon waking, after meals)

Lifestyle Modification

Dietary Modification

  • Patients should be advised to gradually increase their soluble dietary fiber
    • If possible, dietary fiber via fruits, vegetables, legumes and whole grains should be increased to 25-30 g/day
    • If this is not effective, commercial soluble fiber supplements (bulk-producing laxatives) may be added, avoid if bloating is present
  • Patients may be encouraged to maintain adequate hydration (2-2.5 L/day), though increased fluid intake does not appear to relieve chronic constipation except in those who are dehydrated
  • Estimate caloric intake as caloric restriction may result in constipation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 2 days ago
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.